Randal J Kirk
CIK 1091823 · Executive Chairman · last filed 2026-03-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
XON price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
RADFORD, VA 24141
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PGEN | Director | 477,492 | $6.04 | $2.88M | $42.06M | 40 | 2026-03-16 |
| AQB | 10%+ Owner | 375 | $1.15 | $431 | $714.5K | 11 | 2021-11-24 |
| PRECIGEN, INC. (XON) Delisted | Executive Chairman | 176,628 | — | — | $206.60M | 80 | 2020-01-07 |
| Theriva Biologics, Inc. (SYN) Delisted | 10%+ Owner | 23,449 | $1.02 | $23.9K | $20.80M | 4 | 2019-04-03 |
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | Director | 3,601,994 | $0.87 | $3.12M | $43.29M | 20 | 2018-10-09 |
| PRPO | 10%+ Owner | 1,689 | $19.35 | $32.7K | -$10.1K | 3 | 2018-08-30 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | 10%+ Owner | 3,917,041 | — | — | $39.79M | 39 | 2018-08-28 |
| Fibrocell Science, Inc. (FCSC) Delisted | 10%+ Owner | 426,719 | — | — | $41.32M | 4 | 2017-03-10 |
| OGEN | 10%+ Owner | 805 | $0.40 | $321 | $8.55M | 3 | 2016-07-05 |
| Precipio, Inc. (TBIO) Delisted | 10%+ Owner | 5,593 | $0.00 | $1 | $4.47M | 5 | 2016-01-11 |
| CLINICAL DATA INC (CLDA) Delisted | Director | 0 | — | — | $49.60M | 10 | 2011-04-12 |
| NEW RIVER PHARMACEUTICALS INC (NRPH) Delisted | Chairman, President and CEO | — | — | — | $0 | 1 | 2007-01-31 |
Recent Filings · Page 3 of 24
232 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-12-29 | PGEN | Buy (P) | +96,686 | $136.3K | EDGAR |
| 2023-08-17 | PGEN | — | — | $0 | EDGAR |
| 2023-08-17 | PGEN | Buy (P) | +500,000 | $757.6K | EDGAR |
| 2023-03-13 | PGEN | Grant (A) | +85,470 | $100.0K | EDGAR |
| 2023-02-24 | PGEN | Exer (M) | +123,152 | $0 | EDGAR |
| 2023-01-31 | PGEN | Buy (P) | +11,428,571 | $20.00M | EDGAR |
| 2023-01-06 | PGEN | Exer (M) | +3,443 | $0 | EDGAR |
| 2022-10-07 | PGEN | Other (J) | +1,054,463 | $0 | EDGAR |
| 2022-03-28 | PGEN | Exer (M) | +32,425 | $0 | EDGAR |
| 2022-02-24 | PGEN | — | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.